In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy

Paul A Foster; Simon P Newman; Surinder K Chander; Chloe Stengel; Roma Jhalli; Lawrence L W Woo; Barry V L Potter; Michael J Reed; Atul Purohit

doi:10.1158/1078-0432.CCR-06-0632

In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy

Paul A Foster, Simon P Newman, Surinder K Chander, Chloe Stengel, Roma Jhalli, Lawrence L W Woo, Barry V L Potter, Michael J Reed, Atul Purohit

Research output: Contribution to journal › Article › peer-review

54 Citations (Scopus)

Abstract

Steroid sulfatase (STS) inhibitors that can decrease or prevent the biosynthesis of estrogenic steroids via the sulfatase route may play an important role in the treatment of breast cancer. We compare the in vivo efficacy of two potent STS inhibitors, STX64 and STX213, in a xenograft breast cancer model.

Original language	English
Pages (from-to)	5543-9
Number of pages	7
Journal	Clinical Cancer Research
Volume	12
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-06-0632
Publication status	Published - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-06-0632

Cite this

@article{7c305159832046af8f2dc60be1d17f15,

title = "In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy",

abstract = "Steroid sulfatase (STS) inhibitors that can decrease or prevent the biosynthesis of estrogenic steroids via the sulfatase route may play an important role in the treatment of breast cancer. We compare the in vivo efficacy of two potent STS inhibitors, STX64 and STX213, in a xenograft breast cancer model.",

author = "Foster, {Paul A} and Newman, {Simon P} and Chander, {Surinder K} and Chloe Stengel and Roma Jhalli and Woo, {Lawrence L W} and Potter, {Barry V L} and Reed, {Michael J} and Atul Purohit",

year = "2006",

doi = "10.1158/1078-0432.CCR-06-0632",

language = "English",

volume = "12",

pages = "5543--9",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

number = "18",

}

TY - JOUR

T1 - In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy

AU - Foster, Paul A

AU - Newman, Simon P

AU - Chander, Surinder K

AU - Stengel, Chloe

AU - Jhalli, Roma

AU - Woo, Lawrence L W

AU - Potter, Barry V L

AU - Reed, Michael J

AU - Purohit, Atul

PY - 2006

Y1 - 2006

N2 - Steroid sulfatase (STS) inhibitors that can decrease or prevent the biosynthesis of estrogenic steroids via the sulfatase route may play an important role in the treatment of breast cancer. We compare the in vivo efficacy of two potent STS inhibitors, STX64 and STX213, in a xenograft breast cancer model.

AB - Steroid sulfatase (STS) inhibitors that can decrease or prevent the biosynthesis of estrogenic steroids via the sulfatase route may play an important role in the treatment of breast cancer. We compare the in vivo efficacy of two potent STS inhibitors, STX64 and STX213, in a xenograft breast cancer model.

U2 - 10.1158/1078-0432.CCR-06-0632

DO - 10.1158/1078-0432.CCR-06-0632

M3 - Article

C2 - 17000691

SN - 1078-0432

VL - 12

SP - 5543

EP - 5549

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this